ACVR1 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “ACVR1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 9+ pipeline drugs in ACVR1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ACVR1 protein inhibitors: Overview
The human activin A receptor type I (ACVR1) gene also known as ALK2, is located in chromosome 2q23-q24 and encodes for the 509 amino acid protein. Activin A receptor type I (ACVR1) encodes for a bone morphogenetic protein type I receptor of the TGF? receptor superfamily. It is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation. Moreover, ACVR1 has been extensively studied for its causal role in fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterised by progressive heterotopic ossification. ACVR1 is linked to different pathologies, including cardiac malformations and alterations in the reproductive system. The first small molecule inhibitor of ALK2 was dorsomorphin, identified through a classical BMP ventralization assay in zebrafish embryos. Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in Diffuse intrinsic pontine glioma (DIPG), nor to screen currently available inhibitors in patient-derived tumour models.
Report Highlights
This segment of the ACVR1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ACVR1 protein inhibitors Emerging Drugs
Further product details are provided in the report……..
ACVR1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ACVR1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
ACVR1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ACVR1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ACVR1 protein inhibitors drugs.
ACVR1 protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “ACVR1 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 9+ pipeline drugs in ACVR1 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
ACVR1 protein inhibitors: Overview
The human activin A receptor type I (ACVR1) gene also known as ALK2, is located in chromosome 2q23-q24 and encodes for the 509 amino acid protein. Activin A receptor type I (ACVR1) encodes for a bone morphogenetic protein type I receptor of the TGF? receptor superfamily. It is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation. Moreover, ACVR1 has been extensively studied for its causal role in fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterised by progressive heterotopic ossification. ACVR1 is linked to different pathologies, including cardiac malformations and alterations in the reproductive system. The first small molecule inhibitor of ALK2 was dorsomorphin, identified through a classical BMP ventralization assay in zebrafish embryos. Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in Diffuse intrinsic pontine glioma (DIPG), nor to screen currently available inhibitors in patient-derived tumour models.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ACVR1 protein inhibitors R&D. The therapies under development are focused on novel approaches for ACVR1 protein inhibitors.
This segment of the ACVR1 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ACVR1 protein inhibitors Emerging Drugs
- Momelotinib: Sierra Oncology
- BLU-782: Turning Point Therapeutics
Further product details are provided in the report……..
ACVR1 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different ACVR1 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on ACVR1 protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
ACVR1 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses ACVR1 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ACVR1 protein inhibitors drugs.
ACVR1 protein inhibitors Report Insights
- ACVR1 protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing ACVR1 protein inhibitors drugs?
- How many ACVR1 protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ACVR1 protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ACVR1 protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ACVR1 protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sierra Oncology
- Incyte Corporation
- Blueprint Medicines
- Sumitomo Dainippon Pharma Oncology
- Daiichi Sankyo Company
- Keros Therapeutics
- BioCryst Pharmaceuticals
- Momelotinib
- INCB 000928
- BLU 782
- Itacnosertib
- DS 6016
- KER 047
- KTI mAb 2.1
- KTI 2338
- BCX 9499
- BCX 9250
Introduction
Executive Summary
ACVR1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ACVR1 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Momelotinib: Sierra Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
KER 047: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
DS 6016: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCX 9499: BioCryst Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ACVR1 protein inhibitors Key Companies
ACVR1 protein inhibitors Key Products
ACVR1 protein inhibitors- Unmet Needs
ACVR1 protein inhibitors- Market Drivers and Barriers
ACVR1 protein inhibitors- Future Perspectives and Conclusion
ACVR1 protein inhibitors Analyst Views
ACVR1 protein inhibitors Key Companies
Appendix
Executive Summary
ACVR1 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
ACVR1 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Momelotinib: Sierra Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
KER 047: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
DS 6016: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BCX 9499: BioCryst Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
ACVR1 protein inhibitors Key Companies
ACVR1 protein inhibitors Key Products
ACVR1 protein inhibitors- Unmet Needs
ACVR1 protein inhibitors- Market Drivers and Barriers
ACVR1 protein inhibitors- Future Perspectives and Conclusion
ACVR1 protein inhibitors Analyst Views
ACVR1 protein inhibitors Key Companies
Appendix